SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-110371"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-110371" > Assessment of Novel...

Assessment of Novel Molecular Prognostic Markers in Chronic Lymphocytic Leukemia

Bin Kaderi, Mohamed Arifin, 1978- (författare)
Uppsala universitet, Hematologi och immunologi, Molecular Haematology
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet. Medicinska fakulteten. Institutionen för genetik och patologi. Hematologi och immunologi. (creator_code:org_t)
ISBN 978-91-554-7677-9
Uppsala : Acta Universitatis Upsaliensis, 2010
Engelska 77 s.
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 507
Läs hela texten (fulltext)
  • Doktorsavhandling (övrigt vetenskapligt)
Abstract Ämnesord
Stäng  
  • The clinical course of chronic lymphocytic leukemia (CLL) is highly heterogeneous, which has prompted the search for biomarkers that can predict prognosis in this disease. The IGHV gene mutation status and certain genomic aberrations have been identified as reliable prognostic markers of clinical outcome for this disorder. However, the search for more feasible prognostic markers in CLL is still being pursued. Recently, certain single nucleotide polymorphisms (SNPs) in the GNAS1, BCL2 and MDM2 genes and the RNA expression levels of the LPL, ZAP70, TCL1, CLLU1 and MCL1 genes were suggested as novel prognostic markers in CLL. In papers I-III, we performed genotyping analyses of the GNAS1 T393C, BCL2 -938C>A and MDM2 SNP309 polymorphisms in 268-418 CLL patients and related the genotypes with clinical data. Association studies between the polymorphisms and established prognostic markers (i.e. IGHV mutation status, genomic aberrations, CD38 expression) were also performed. Our studies did not find any significant relationship between these SNPs with either clinical outcome or other known prognostic markers in CLL. In paper IV, we measured the RNA expression levels of LPL, ZAP70, TCL1, CLLU1 and MCL1 in 252 CLL cases and correlated these levels with clinical outcome. Here, we verified that high expression of all these RNA-based markers, except MCL1, were associated with an unfavourable prognosis. We also confirmed a close relationship between IGHV mutation status and the RNA-based markers, especially for LPL and CLLU1 expression. Among the RNA-based markers, multivariate analysis revealed LPL expression as the strongest independent prognostic marker for overall survival and time to treatment. Furthermore, the RNA-based markers could add further prognostic information to established markers in subgroups of patients, with LPL expression status giving the most significant results. In summary, data from papers I-III could not verify the GNAS1 T393C, BCL2 -938C>A and MDM2 SNP309 polymorphisms as prognostic markers in CLL. Future SNP markers must hence be confirmed in large, independent cohorts before being proposed as prognostic marker in CLL. In paper IV, we conclude that LPL expression appears to be the strongest among the RNA-based markers for CLL prognostication. Further efforts to standardize LPL quantification are required before it can be applied in the clinical laboratory to predict clinical outcome in this disease.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)
NATURVETENSKAP  -- Biologiska vetenskaper -- Genetik (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Genetics (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Biomedicinsk laboratorievetenskap/teknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Biomedical Laboratory Science/Technology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

chronic lymphocytic leukemia
prognostic markers
single nucleotide polymorphisms
RNA-based markers
MEDICINE Dermatology and venerology,clinical genetics, internal medicine Clinical genetics Medical genetics
MEDICIN Dermatologi och venerologi, klinisk genetik, invärtesmedicin Klinisk genetik Medicinsk genetik
NATURAL SCIENCES Biology Cell and molecular biology Genetics
NATURVETENSKAP Biologi Cell- och molekylärbiologi Genetik
MEDICINE Dermatology and venerology,clinical genetics, internal medicine Clinical genetics
MEDICIN Dermatologi och venerologi, klinisk genetik, invärtesmedicin Klinisk genetik
INTERDISCIPLINARY RESEARCH AREAS Caring sciences Medical laboratory science
TVÄRVETENSKAPLIGA FORSKNINGSOMRÅDEN Vårdvetenskap Medicinsk laboratorievetenskap
MEDICINE Surgery Oncology
MEDICIN Kirurgi Onkologi
MEDICINE Dermatology and venerology,clinical genetics, internal medicine Internal medicine Haematology
MEDICIN Dermatologi och venerologi, klinisk genetik, invärtesmedicin Invärtesmedicin Hematologi
Clinical Genetics
Klinisk genetik
Molekylär medicin
Molecular Medicine
Oncology
Onkologi
Medicin
Medicine
Medical Genetics
Medicinsk genetik

Publikations- och innehållstyp

dok (ämneskategori)
vet (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Bin Kaderi, Moha ...
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Medicinska grund ...
och Medicinsk geneti ...
NATURVETENSKAP
NATURVETENSKAP
och Biologiska veten ...
och Genetik
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Medicinsk biotek ...
och Biomedicinsk lab ...
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Cancer och onkol ...
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Hematologi
Delar i serien
Digital Comprehe ...
Av lärosätet
Uppsala universitet

Sök utanför SwePub

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy